Cost-effectiveness of BRCA1/BRCA2 Variant Reclassification and Recontact for Hereditary Breast and Ovarian Cancer in the United States.
- DOI
- 10.1016/j.gim.2026.102697
- Published
- 2026 Aug 26
- Container
- Genetics in medicine : official journal of the American College of Medical Genetics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.gim.2026.102697,
title = {Cost-effectiveness of BRCA1/BRCA2 Variant Reclassification and Recontact for Hereditary Breast and Ovarian Cancer in the United States.},
author = {Guzauskas GF and Berger SM and O'Connor R and Kim S and Topper S and Chao E and Horton C and Hoang L and Veenstra DL and Chung WK},
year = {2026},
journal = {Genetics in medicine : official journal of the American College of Medical Genetics},
doi = {10.1016/j.gim.2026.102697},
url = {https://doi.org/10.1016/j.gim.2026.102697}
}RIS
TY - JOUR TI - Cost-effectiveness of BRCA1/BRCA2 Variant Reclassification and Recontact for Hereditary Breast and Ovarian Cancer in the United States. AU - Guzauskas GF AU - Berger SM AU - O'Connor R AU - Kim S AU - Topper S AU - Chao E AU - Horton C AU - Hoang L AU - Veenstra DL AU - Chung WK PY - 2026 JO - Genetics in medicine : official journal of the American College of Medical Genetics DO - 10.1016/j.gim.2026.102697 UR - https://doi.org/10.1016/j.gim.2026.102697 ER -
APA
GF, G., SM, B., R, O., S, K., S, T., E, C., C, H., L, H., DL, V., & WK, C. (2026). Cost-effectiveness of BRCA1/BRCA2 Variant Reclassification and Recontact for Hereditary Breast and Ovarian Cancer in the United States.. Genetics in medicine : official journal of the American College of Medical Genetics. https://doi.org/10.1016/j.gim.2026.102697
Source records
- pubmed · retrieved 2026-09-25T17:08:19.287Z